Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Evolus Inc (EOLS)

Evolus Inc (EOLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, launched commercial operations in Great Britain and shipped the first...

EOLS : 8.80 (+4.27%)
Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, this month celebrated the conclusion of certain royalty payments...

EOLS : 8.80 (+4.27%)
Evolus Announces Inducement Grants for New Chief Financial Officer

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Compensation Committee of the Board of Directors...

EOLS : 8.80 (+4.27%)
Evolus Appoints Sandra Beaver as Chief Financial Officer

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has named Sandra Beaver as its Chief Financial Officer, effective...

EOLS : 8.80 (+4.27%)
Evolus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of its management team will be participating...

EOLS : 8.80 (+4.27%)
Newly Published Post Hoc Analysis Evaluates Efficacy of Jeuveau® in Adult Males Compared to BOTOX®

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that a peer-reviewed, post hoc analysis published...

EOLS : 8.80 (+4.27%)
Which Growth Stock Is a Better Buy Right Now -- AbbVie or InMode?

These beaten-down stocks share a favorable outlook for their aesthetic segments.

AGN.AX : 0.455 (+3.41%)
ABBV : 141.99 (+2.65%)
INMD : 31.82 (+5.26%)
EOLS : 8.80 (+4.27%)
Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates

Evolus, Inc. (EOLS) delivered earnings and revenue surprises of -58.33% and 0.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

EOLS : 8.80 (+4.27%)
CGC : 3.14 (+7.90%)
Evolus Reports Second Quarter 2022 Results and Provides Business Update

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the second quarter ended June...

EOLS : 8.80 (+4.27%)
Is Deciphera Pharmaceuticals (DCPH) Outperforming Other Medical Stocks This Year?

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Evolus, Inc. (EOLS) have performed compared to their sector so far this year.

DCPH : 19.04 (+4.04%)
EOLS : 8.80 (+4.27%)

Barchart Exclusives

Covered Call Screener Results For October 4th
Buying 100 shares of PDD would cost $6,647. The December 70 strike call option was trading yesterday around $7.10, generating $710 in premium per contract for covered call sellers. Selling the call option generates an income of 11.96% in 72 days, equaling around 59.79% annualized. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar